

## Tepadina<sup>®</sup> (thiotepa) – New Drug Approval

- On January 26, 2017, the [FDA approved](#) Adienne's [Tepadina \(thiotepa\)](#) for the following indications:
  - To reduce the risk of graft rejection when used in conjunction with high-dose busulfan ([Busulfex<sup>®</sup>](#)) and [cyclophosphamide](#) as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia
  - For treatment of adenocarcinoma of the breast or ovary
  - For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities
  - For treatment of superficial papillary carcinoma of the urinary bladder
- [Thiotepa](#) is also generically available as a 15 mg vial. Thiotepa shares Tepadina's indications except for class 3 beta-thalassemia. In addition, while largely superseded by other treatments, thiotepa has been effective against other lymphomas, such as lymphosarcoma and Hodgkin's disease.
- The efficacy of Tepadina for pediatric patients with class 3 beta-thalassemia who underwent allogeneic HSCT was evaluated in a retrospective study of 25 patients.
  - The incidence of graft rejection was 0% (95% CI: 0, 0.12).
  - In 51 patients who received the same preparative regimen, historically, without Tepadina, the incidence of graft rejection reported was 25.5% (95% CI: 0.13, 0.37).
- Tepadina carries a boxed warning for severe myelosuppression and carcinogenicity.
- Tepadina is contraindicated in patients with severe hypersensitivity to thiotepa and concomitant use with live or attenuated vaccines.
- Other warnings and precautions of Tepadina include cutaneous toxicity, hepatic veno-occlusive disease, central nervous system toxicity, and embryo-fetal toxicity.
- The most common adverse events (> 10%) with Tepadina use were neutropenia, anemia, thrombocytopenia, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated bilirubin, mucositis, cytomegalovirus infection, hemorrhage, diarrhea, hematuria and rash.
- Tepadina is dosed according to body weight.
  - For class 3 beta-thalassemia and adenocarcinoma of the breast or ovary, Tepadina is administered intravenously.
  - For malignant effusions, Tepadina is administered by the intracavitary route.
  - For papillary carcinoma of the urinary bladder, Tepadina is administered into the bladder by catheter.
  - For further details, Tepadina's prescribing information should be consulted for dosing in each indication.

- Adienne's launch plans for Tepadina are pending. Tepadina will be available as 15 mg and 100 mg vials.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.